Market Place
Sourcing Support
Acurx Pharmaceuticals Reports Q2 Results and Business Update
12 Aug 2025 //
PR NEWSWIRE
Acurx Pharmaceuticals` Q2 2025 Financial Results and Update
24 Jul 2025 //
PR NEWSWIRE
Acurx Pharmaceuticals Presents Results at FASEB Conference
09 Jun 2025 //
PR NEWSWIRE
Acurx Pharmaceuticals Reports First Quarter Results and Update
13 May 2025 //
PR NEWSWIRE
Acurx Pharmaceuticals Reports Q4 and Full Year 2024 Results
18 Mar 2025 //
PR NEWSWIRE
Acurx Pharmaceuticals Closes $1.1M Registered Direct Offering
10 Mar 2025 //
PR NEWSWIRE
Acurx Pharmaceuticals Announces $1.1 M Registered Direct Offering
07 Mar 2025 //
PR NEWSWIRE
Acurx Publishes Data On Ibezapolstat`s Gut Microbiome Effects
03 Mar 2025 //
PR NEWSWIRE
Acurx publishes positive results on Ibezapolstat for CDI.
24 Feb 2025 //
PR NEWSWIRE
Acurx Pharma Patent in Japan for DNA Polymerase IIIC Inhibitors
19 Feb 2025 //
PR NEWSWIRE
Acurx Closes $2.5M Offering Under Nasdaq Market Rules
07 Jan 2025 //
PR NEWSWIRE
Acurx Gets EMA Guidance For Ibezapolstat Ph3 For C. Difficile
06 Jan 2025 //
PR NEWSWIRE
Acurx Pharma Announces $2.5M Offering Priced At Nasdaq Rules
06 Jan 2025 //
PR NEWSWIRE
Acurx Pharma To Present At Microcap Conference In January 2025
11 Dec 2024 //
ACCESSWIRE
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile
09 Dec 2024 //
PR NEWSWIRE
Acurx Participates in Peggy Lillis Foundation CDI Symposium
18 Nov 2024 //
PR NEWSWIRE
Acurx Pharma, Inc. Reports Q3 2024 Results & Business Update
13 Nov 2024 //
PR NEWSWIRE
Acurx Presents New Analyses From Ibezapolstat Ph2b Trial At IDWeek
21 Oct 2024 //
PR NEWSWIRE
Acurx PharmaTo Participate In Spartan Capital Investor Conference
17 Oct 2024 //
PR NEWSWIRE
Acurx To Discuss Q3 2024 Results On November 13, 2024
16 Oct 2024 //
PR NEWSWIRE
Acurx Announces Ibezapolstat And ACX-375 Results in CDI
26 Sep 2024 //
PR NEWSWIRE
Acurx Shares Ibezapolstat Research at International C. difficile Symposium
24 Sep 2024 //
PR NEWSWIRE
Acurx Pharmaceuticals To Participate In H.C. Wainwright Conference
26 Aug 2024 //
PR NEWSWIRE
Acurx Pharmaceuticals Reports Q2 2024 Results And Business Update
09 Aug 2024 //
PR NEWSWIRE
Acurx Gets New Patent For Ibezapolstat To Treat CDI
17 Jul 2024 //
PR NEWSWIRE
Acurx Pharmaceuticals To Discuss Q2 Results On August 9 Call
16 Jul 2024 //
PR NEWSWIRE
Acurx Presents Ibezapolstat Phase 2 Results For CDI At Scientific Conference
15 Jul 2024 //
PR NEWSWIRE
Acurx Pharmaceuticals Reports Q1 2024 Results, Business Update
15 May 2024 //
PR NEWSWIRE
Acurx Announces Successful Ibezapolstat Phase 2 Meeting, Phase 3 Readiness
15 May 2024 //
PR NEWSWIRE
Acurx Presents Ibezapolstat Phase 2 Results At ESCMID 2024
02 May 2024 //
PR NEWSWIRE
Acurx Presents Ibezapolostat Phase 2 Data at ESCMID 2024
25 Apr 2024 //
PR NEWSWIRE
Acurx Pharma to Discuss Q1 2024 Results and Business Update on May 15
23 Apr 2024 //
PR NEWSWIRE
Acurx Pharma to Discuss Fourth Quarter and Full Year 2023 Financial Results
04 Mar 2024 //
PR NEWSWIRE
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat
27 Feb 2024 //
PR NEWSWIRE
Acurx Announces Positive Clinical Cure Data for Ibezapolstat from Phase 2b Trial
29 Jan 2024 //
PR NEWSWIRE
Acurx to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
23 Jan 2024 //
PR NEWSWIRE
Acurx Announces Positive Microbiology and Microbiome Data for Ibezapolstat
17 Jan 2024 //
PR NEWSWIRE
Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
PR NEWSWIRE
Acurx Announces Positive Phase 2b Results with Ibezapolstat
11 Dec 2023 //
PR NEWSWIRE
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results
14 Nov 2023 //
PR NEWSWIRE
Acurx Announces Ibezapolstat Ph 2 Efficacy Results with 96% Clinical Cure Rate
02 Nov 2023 //
PR NEWSWIRE
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results
25 Oct 2023 //
PR NEWSWIRE
Acurx Announces Ibezapolstat Scientific Posters and Presentations
19 Oct 2023 //
PR NEWSWIRE
Acurx Announces Completion and Early Discontinuation of the Ibezapolstat
02 Oct 2023 //
PR NEWSWIRE
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline
12 Sep 2023 //
PR NEWSWIRE
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results
14 Aug 2023 //
PR NEWSWIRE
Acurx to Discuss Second Quarter 2023 Financial Results
24 Jul 2023 //
PR NEWSWIRE
Acurx to Participate in the Maxim Group LLC Healthcare Conference
15 Jun 2023 //
PR NEWSWIRE
Acurx Pharma Announces Pricing of $4.0 m Registered Direct Offering
16 May 2023 //
PR NEWSWIRE
Acurx Pharma Reports 1Q 2023 Results and Provides Business Update
12 May 2023 //
PR NEWSWIRE
Acurx Pharmaceuticals to Discuss 1Q 2023 FYR and Provide Business Update
05 May 2023 //
ACCESSWIRE
FDA Accepts Interim Analysis Plan for Ongoing Ph2b Ibezapolstat Clinical Trial
11 Apr 2023 //
PR NEWSWIRE
Acurx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
16 Mar 2023 //
PR NEWSWIRE
Acurx Pharma to Discuss Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
PR NEWSWIRE
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results
14 Nov 2022 //
PRNEWSWIRE
Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022
26 Oct 2022 //
PRNEWSWIRE
Acurx Announces Scientific Oral and Poster Presentations at IDWeek
17 Oct 2022 //
PRNEWSWIRE
Acurx Pharma to Discuss 2022 Second Quarter Financial Results
04 Aug 2022 //
PRNEWSWIRE
Acurx Announces New Data Presentations from Ongoing PII Trial of Ibezapolstat
02 Aug 2022 //
PRNEWSWIRE
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
25 Jul 2022 //
PRNEWSWIRE
